Your Health, We Care
In a single-arm trial involving 108 previously treated patients with unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, TRUSELTIQ demonstrated its efficacy. The primary efficacy endpoints were the objective response rate (ORR) and duration of response (DoR) as assessed by an independent review committee.
The results showed that the objective response rate was 23%, including a complete response rate of 1% and a partial response rate of 22%. The median duration of response was 5.0 months, and the median time to response was 3.6 months.
FDA，2021.05
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
